

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT3135068

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
MONIQUE CAPRON	09/19/2014
MOHAMED EL NADY	09/24/2014
JEAN-FREDERIC COLOMBEL	09/12/2014
GILLES RIVEAU	10/17/2014
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	UNIVERSITE DU DROIT ET DE LA SANTE DE LILLE 2
<b>Street Address:</b>	42, RUE PAUL DUEZ
<b>City:</b>	LILLE
<b>State/Country:</b>	FRANCE
<b>Postal Code:</b>	F-59800
<b>Name:</b>	INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
<b>Street Address:</b>	101, RUE DE TOLBIAC
<b>City:</b>	PARIS CEDEX 13
<b>State/Country:</b>	FRANCE
<b>Postal Code:</b>	F-75654
<b>Name:</b>	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
<b>Street Address:</b>	3, RUE MICHEL-ANGE
<b>City:</b>	PARIS
<b>State/Country:</b>	FRANCE
<b>Postal Code:</b>	F-75794
<b>Name:</b>	CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE
<b>Street Address:</b>	2, AVENUE OSCAR LAMBRET
<b>City:</b>	LILLE CEDEX
<b>State/Country:</b>	FRANCE
<b>Postal Code:</b>	F-59037
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	14377006

**CORRESPONDENCE DATA****Fax Number:** (703)685-0573

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 7035212297**Email:** mpessagno@young-thompson.com**Correspondent Name:** YOUNG & THOMPSON**Address Line 1:** 209 MADISON STREET**Address Line 2:** SUITE 500**Address Line 4:** ALEXANDRIA, VIRGINIA 22314

<b>ATTORNEY DOCKET NUMBER:</b>	0508-1378
<b>NAME OF SUBMITTER:</b>	BENOIT CASTEL
<b>SIGNATURE:</b>	/Benoit Castel/
<b>DATE SIGNED:</b>	12/05/2014

<b>NAME OF SUBMITTER:</b>	BENOIT CASTEL
<b>SIGNATURE:</b>	/Benoit Castel/
<b>DATE SIGNED:</b>	12/05/2014

<b>SIGNATURE:</b>	/Benoit Castel/
<b>DATE SIGNED:</b>	12/05/2014

<b>DATE SIGNED:</b>	12/05/2014
---------------------	------------

**Total Attachments: 6**

source=DEC-ASSMT#page1.tif

source=DEC-ASSMT#page2.tif

source=DEC-ASSMT#page3.tif

source=DEC-ASSMT#page4.tif

source=DEC-ASSMT#page5.tif

source=DEC-ASSMT#page6.tif

### ASSIGNMENT AND INVENTOR'S DECLARATION

WHEREAS I/we, the undersigned inventor(s), hereafter also referred to as "assignor(s)", have invented certain new and useful improvements described in the application identified below; and

WHEREAS, UNIVERSITE DU DROIT ET DE LA SANTE DE LILLE 2,

INSERM (Institut National de la Santé et de la Recherche Médicale),

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE and

CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE, hereinafter referred to as "assignee(s)", whose address is \_\_\_\_\_, is desirous of acquiring the entire right, title and interest in and to the application and invention, and to any United States patents to be obtained therefor;

NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which is hereby acknowledged, I/we, the above-named assignor(s), hereby sell, assign and transfer to the above named assignee(s), its successors and assigns, the entire right, title and interest in the application and the invention disclosed therein for the United States of America, including all divisions, and continuations thereof, and all Letters Patent of the United States that may be granted thereon, and all reissues thereof, including any right to bring or maintain an action for infringement under the provisional rights granted pursuant to Title 35, Section 154 of the United States Code or any other cause of action for acts which would constitute infringement occurring prior to this assignment, and including the right to claim priority under the International Convention of Paris (1883), as amended, of or in any corresponding foreign patent application, and I/we request the Director of the U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee(s), its successors and assigns.

As a below named inventor, I hereby declare that:

This assignment and declaration is directed to:


- ☐ The attached application, or  
☐ United States Application or PCT International Application Number \_\_\_\_\_  
filed on \_\_\_\_\_ (Confirmation No. \_\_\_\_\_).

The application is entitled: **28 KDA GST PROTEINS FROM SCHISTOSOMA FOR THE USE THEREOF IN THE TREATMENT OF INFLAMMATORY AUTOIMMUNE DISEASES GENERATING A TH1 AND/OR TH17 RESPONSE**

The above-identified application was made or was authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this assignment with declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

Given Name(s)	Monique	Family Name/Surname(s)	CAPRON
Inventor's Signature:			Date 13/9/2014
Given Name(s)	Mohamed	Family Name/Surname(s)	EL NADY
Inventor's Signature:			Date

### ASSIGNMENT AND INVENTOR'S DECLARATION

WHEREAS I/we, the undersigned inventor(s), hereafter also referred to as "assignor(s)", have invented certain new and useful improvements described in the application identified below; and

WHEREAS, UNIVERSITE DU DROIT ET DE LA SANTE DE LILLE 2,

INSERM (Institut National de la Santé et de la Recherche Médicale),

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE and

CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE, hereinafter referred to as "assignee(s)", whose address is \_\_\_\_\_, is desirous of acquiring the entire right, title and interest in and to the application and invention, and to any United States patents to be obtained therefor;

NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which is hereby acknowledged, I/we, the above-named assignor(s), hereby sell, assign and transfer to the above named assignee(s), its successors and assigns, the entire right, title and interest in the application and the invention disclosed therein for the United States of America, including all divisions, and continuations thereof, and all Letters Patent of the United States that may be granted thereon, and all reissues thereof, including any right to bring or maintain an action for infringement under the provisional rights granted pursuant to Title 35, Section 154 of the United States Code or any other cause of action for acts which would constitute infringement occurring prior to this assignment, and including the right to claim priority under the International Convention of Paris (1883), as amended, of or in any corresponding foreign patent application, and I/we request the Director of the U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee(s), its successors and assigns.

As a below named inventor, I hereby declare that:

This assignment and declaration is directed to:


- ☐ The attached application, or  
☐ United States Application or PCT International Application Number \_\_\_\_\_ filed on \_\_\_\_\_ (Confirmation No. \_\_\_\_\_).

The application is entitled: **28 KDA GST PROTEINS FROM SCHISTOSOMA FOR THE USE THEREOF IN THE TREATMENT OF INFLAMMATORY AUTOIMMUNE DISEASES GENERATING A TH1 AND/OR TH17 RESPONSE**

The above-identified application was made or was authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this assignment with declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

Given Name(s)	Monique	Family Name/Surname(s)	CAPRON
Inventor's Signature:			Date
Given Name(s)	Mohamed	Family Name/Surname(s)	EL NADY
Inventor's Signature:			Date 24/3/2014

### ASSIGNMENT AND INVENTOR'S DECLARATION

WHEREAS I/we, the undersigned inventor(s), hereafter also referred to as "assignor(s)", have invented certain new and useful improvements described in the application identified below; and

WHEREAS, UNIVERSITE DU DROIT ET DE LA SANTE DE LILLE 2,  
INSERM (Institut National de la Santé et de la Recherche Médicale),  
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE and  
CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE, hereinafter referred to as "assignee(s)",  
whose address is \_\_\_\_\_, is desirous of acquiring the entire right, title and interest in and to the application and  
invention, and to any United States patents to be obtained therefor;

NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which is hereby acknowledged,  
I/we, the above-named assignor(s), hereby sell, assign and transfer to the above named assignee(s), its  
successors and assigns, the entire right, title and interest in the application and the invention disclosed therein  
for the United States of America, including all divisions, and continuations thereof, and all Letters Patent of the  
United States that may be granted thereon, and all reissues thereof, including any right to bring or maintain an  
action for infringement under the provisional rights granted pursuant to Title 35, Section 154 of the United  
States Code or any other cause of action for acts which would constitute infringement occurring prior to this  
assignment, and including the right to claim priority under the International Convention of Paris (1883), as  
amended, of or in any corresponding foreign patent application, and I/we request the Director of the U.S.  
Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the  
application to the assignee(s), its successors and assigns.

As a below named inventor, I hereby declare that:

This assignment and  
declaration is directed to:

- ☐ The attached application, or  
☐ United States Application or PCT International Application Number \_\_\_\_\_  
filed on \_\_\_\_\_ (Confirmation No. \_\_\_\_\_).

The application is entitled: **28 KDA GST PROTEINS FROM SCHISTOSOMA FOR THE USE THEREOF IN  
THE TREATMENT OF INFLAMMATORY AUTOIMMUNE DISEASES GENERATING A TH1 AND/OR TH17  
RESPONSE**

The above-identified application was made or was authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this assignment with declaration is punishable  
under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

Given Name(s)	Monique	Family Name/Surname(s)	CAPRON
Inventor's Signature:			Date
Given Name(s)	Mohamed	Family Name/Surname(s)	EL NADY
Inventor's Signature:			Date

Given Name(s)	Jean-Frédéric	Family Name/Surname(s)	COLOMBEL
Inventor's Signature:			Date
Given Name(s)	Gilles	Family Name/Surname(s)	RIVEAU
Inventor's Signature:			Date

## ASSIGNMENT AND INVENTOR'S DECLARATION

WHEREAS I/we, the undersigned inventor(s), hereafter also referred to as "assignor(s)", have invented certain new and useful improvements described in the application identified below; and

WHEREAS, UNIVERSITE DU DROIT ET DE LA SANTE DE LILLE 2,  
INSERM (Institut National de la Santé et de la Recherche Médicale),  
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE and  
CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE, hereinafter referred to as "assignee(s)", whose address is \_\_\_\_\_, is desirous of acquiring the entire right, title and interest in and to the application and invention, and to any United States patents to be obtained therefor;

NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which is hereby acknowledged, I/we, the above-named assignor(s), hereby sell, assign and transfer to the above named assignee(s), its successors and assigns, the entire right, title and interest in the application and the invention disclosed therein for the United States of America, including all divisions, and continuations thereof, and all Letters Patent of the United States that may be granted thereon, and all reissues thereof, including any right to bring or maintain an action for infringement under the provisional rights granted pursuant to Title 35, Section 154 of the United States Code or any other cause of action for acts which would constitute infringement occurring prior to this assignment, and including the right to claim priority under the International Convention of Paris (1883), as amended, of or in any corresponding foreign patent application, and I/we request the Director of the U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee(s), its successors and assigns.

As a below named inventor, I hereby declare that:

This assignment and  
declaration is directed to:

- ☐ The attached application, or  
☐ United States Application or PCT International Application Number \_\_\_\_\_  
filed on \_\_\_\_\_ (Confirmation No. \_\_\_\_\_).


The application is entitled: **28 KDA GST PROTEINS FROM SCHISTOSOMA FOR THE USE THEREOF IN THE TREATMENT OF INFLAMMATORY AUTOIMMUNE DISEASES GENERATING A TH1 AND/OR TH17 RESPONSE**

The above-identified application was made or was authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this assignment with declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

Given Name(s)	Monique	Family Name/Surname(s)	CAPRON
Inventor's Signature:		Date	
Given Name(s)	Mohamed	Family Name/Surname(s)	EL NADY
Inventor's Signature:		Date	

Given Name(s)	Jean-Frédéric	Family Name/Surname(s)	COLOMBEL
Inventor's Signature:		Date	
Given Name(s)	Gilles	Family Name/Surname(s)	RIVEAU
Inventor's Signature:		Date	Oct. 17 <sup>th</sup> , 2014